Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer

CHEN YU¹, SHEN-LIN LIU², MING-HAO QI³ and XI ZOU⁴

¹First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046; ²Senior Expert Consultation Center; ³National Clinical Research Base of Traditional Chinese Medicine; ⁴Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

Received June 9, 2013; Accepted November 20, 2013

DOI: 10.3892/mmr.2013.1830

Abstract. Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo. The aim of the present study was to examine the potential advantages of using cinnamaldehyde in combination with chemotherapeutic agents commonly used in colorectal carcinoma (CRC) therapy, as well as to investigate the effect of cinnamaldehyde on chemotherapeutic-associated gene expression. The synergistic interaction of cinnamaldehyde and chemotherapeutic agents on human CRC HT-29 and LoVo cells was evaluated using the combination index (CI) method. The double staining with Annexin V conjugated to fluorescein-isothiocyanate and phosphatidylserine was employed for apoptosis detection. The expression of drug-metabolizing genes, including excision repair cross-complementing 1 (ERCC1), orotate phosphoribosyltransferase (OPRT), thymidylate synthase (TS), breast cancer susceptibility gene 1 (BRCA1) and topoisomerase 1 (TOPO1), all in HT-29 and LoVo cells, with or without the addition of cinnamaldehyde, was examined by quantitative polymerase chain reaction (PCR). Cinnamaldehyde had a synergistic effect on the chemotherapeutic agents cytotoxicity in HT-29 and LoVo cells. In addition, cinnamaldehyde suppressed BRCA1, TOPO1, ERCC1 and TS mRNA expression, except for OPRT expression, which was markedly upregulated. Our findings indicate that cinnamaldehyde appears to be a promising candidate as an adjuvant in combination therapy with 5-fluorouracil (5-FU) and oxaliplatin (OXA), two chemotherapeutic agents used in CRC treatment. The possible mechanisms of its action may involve the regulation of drug-metabolizing genes.

Introduction

Colorectal carcinoma (CRC) is one of the most prevalent types of cancer in Western countries (1,2) and the third most common cancer worldwide, with an incidence of approximately one million cases and 500,000 mortalities annually (3,4). Despite huge efforts to resolve the molecular basis of this disease, it remains a therapeutic challenge for oncologists due to its often late detection and poor prognosis. Currently, there are no standardized treatment protocols, nevertheless the increasing number of active cytotoxic drugs and targeted therapies have placed clinicians in front of a broad spectrum of therapeutic options (5-9). Oxaliplatin (OXA), 5-fluorouracil (5-FU) and irinotecan (IRI) are presently the mainstay of chemotherapeutic treatment for CRC, and OXA/5-FU/iri/leucovorin (LV; FOLFIRI) and folinic acid ([FOL]/5-FU/IRI; FOLFIR) are considered the standard treatment regimens for advanced CRC (5,10). However, the positive response rate of patients to therapy remains <40% (11,12). Hence, better systemic therapies are needed to decrease side effects and improve the clinical outcomes of patients with CRC.

Despite recent advances in chemotherapeutic treatment, the five-year survival rate for CRC remains relatively poor (13), with a median survival of ~25 months (14,15). In addition, antineoplastic agents often achieve antitumor activity at the expense of a practically unacceptable toxicity. OXA, 5-FU and IRI have different mechanisms of action and different toxicity profiles (16). Over the years various attempts have been made to improve the objective response rate to chemotherapy, including different chemotherapeutic agents and their combinations, as well as the use of distinct adjuvants. In general, the rationale for the combination of two or more therapeutic agents is to achieve lower drug doses, reduce toxicity and minimize or delay treatment resistance.

Several compounds traditionally used in Chinese medicine have previously been used as an adjuvant to chemotherapy, demonstrating positive effects, specifically in the sensitization of the last one (17). Cinnamomum cassia Presl. (Lauraceae) has been traditionally used in Chinese medicine to treat dyspepsia, gastritis, blood circulation disturbances and inflammatory diseases (18). Cinnamaldehyde is the main bioactive compo-
Cinnamaldehyde is a food flavoring agent. Several biological activities, including peripheral vasodilatory effect, antitumor, antifungal, cytotoxic and mutagenic/anti-mutagenic activities, have been associated with cinnamaldehyde (19-22).

In our previous studies, we demonstrated that cinnamaldehyde is able to exhibit several biological effects, including antiangiogenic effects (23) as well as chemopreventive (24) and anti-inflammatory activities (25). Other previous studies demonstrated that cinnamaldehyde induced apoptosis in a variety of tumor cell lines, including two human leukemia cell lines HL-60 and K562 (26,27) and human hepatoma PLC/PRF/5 cells (28). Furthermore, cinnamaldehyde also exhibited antiproliferative activity in human colon-derived SW620 and human mammary-derived MCF-7 carcinoma cells (29).

However, despite the various biological activities of cinnamaldehyde, its potential role in cancer therapy has not been clearly addressed. In addition, whether the combination of cinnamaldehyde and chemotherapeutic agents may possibly result in a useful synergistic interaction against CRC cells has not been examined thus far.

Therefore, in order to elucidate the mechanisms possibly involved in the interaction between the cinnamaldehyde and chemotherapeutic agents, we examined the effect of this treatment on apoptosis as well as the expression of drug-metabolizing genes in CRC cells.

Materials and methods

Drugs. Cinnamaldehyde (molecular formula, C6H8O) was obtained as a powder with a purity of 98.6% from the National Institutes for Food and Drug Control (Beijing, China). OXA, 5-FU and IRI were supplied from Jiangsu Hengrui Medicine Company (Jiangsu, China). All reagents were prepared in complete culture medium immediately prior to their use in vitro. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Chemical Company (St. Louis, MO, USA). Annexin V conjugated to fluorescein-isothiocyanate (Annexin V-FITC) Apoptosis Detection kit was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). All other chemicals used were of the highest purity grade available.

Cell culture. The human well-differentiated colon adenocarcinoma cell line HT-29 and poorly differentiated colon adenocarcinoma cell line LoVo were obtained from Shanghai Institute of Cell Biology (Shanghai, China). All cell lines were propagated in RPMI-1640 medium (Gibco-BRL, Grand Island, New York, USA), supplemented with 10% bovine serum albumin, penicillin (100 U/ml)-streptomycin (100 mg/ml), pyruvate, glutamine and insulin at 37°C in a water-saturated atmosphere with 5% CO2.

Measurement of the IC50 (half maximal inhibitory concentration) for cinnamaldehyde and chemotherapeutic agents. Tumor cells in log-phase were trypsinized and seeded at 2x10^3 cells per well into 96-well plates and allowed to attach overnight. The next day, the medium in each well was replaced with fresh medium or medium with various concentrations of drugs in at least five replicate wells and incubated for 48 h. The medium-containing drug was decanted and the IC50 doses for each drug were determined by an MTT assay. The IC50 was defined as the concentration required for 50% inhibition of cell growth. In each experimental plate, 10 wells containing drug-free medium were used as a control and each experiment was repeated at least three times.

Determination of synergism and antagonism. Subconfluent CRC cells were seeded at 2x10^4 cells per well in 96-well plates. Drugs were added either concomitantly or sequentially with six different concentrations of the single agent and six different concentrations of the two agents at their fixed ratio based on their respective individual IC50 values for 48 h. The fractional inhibition of cell proliferation was calculated by comparison to control cultures. Dose-response curves were obtained for each drug and for multiple dilutions of two drugs fixed-ratio combinations. Median effect analysis using the combination index (CI) method of Chou and Talalay (30) was employed to determine the nature of the interaction observed between cinnamaldehyde and chemotherapeutic agents. The CI was defined by the following equation, in which (Dx)1 and (Dx)2 are, respectively, the concentrations for D1 (CI) and D2 (chemotherapeutic agent) alone that give x% inhibition, whereas (D1) and (D2) in the numerator are, respectively, the concentrations of cinnamaldehyde and another drug that produces the identical level of effect in combination.

\[ CI = \frac{(D_1)^1 + (D_2)^2 + \alpha}{(D_1)^2 + (D_2)^2} \]

The alpha value was determined as follows: \( \alpha = 0 \) when drugs were mutually exclusive (i.e., with similar modes of action), while \( \alpha = 1 \) when they were mutually non-exclusive (i.e., with independent modes of action). Finally, the CI values were defined as follows: CI<1 indicated synergy and CI=1 indicated additivity. Each CI ratio was the mean value derived from at least three independent experiments.

Cytotoxicity assay. In vitro drug-induced cytotoxic effects were measured by an MTT assay (31). Briefly, following drug treatment, one-tenth volume of MTT was added to each well and the plate was further incubated at 37°C for 4 h. To solubilize the MTT-formazan product following the removal of the medium, 200 μl of dimethyl sulfoxide was added to each well. Absorbance at 570 nm was measured with a multwell spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). Growth inhibition was calculated as a percentage of the untreated controls, which were not exposed to drugs.

Apoptosis assay. For the apoptosis assay, cells were cultured in a 60 mm Petri dish and allowed to grow to confluency. HT-29 cells were treated with 5 μg/ml cinnamaldehyde and 0.625 μg/ml 5-FU and 6.25 μg/ml OXA and 2.5 μg/ml cinnamaldehyde. LoVo cells were treated with 2.5 μg/ml 5-FU and 2.5 μg/ml cinnamaldehyde. Next, they were exposed to cinnamaldehyde and anticancer drugs added either individually or in combination for 48 h. Subsequently, cells were collected and incubated with Annexin V-FITC (Bender MedSystems,
Quantitative RT-PCR. LoVo and HT-29 cells were seeded on 6-well plates at 5x10^5 cells/ml concentration and treated with cinnamaldehyde at its IC_{50} value for 48 h. Furthermore, cells were harvested with trypsin, washed with phosphate-buffered saline and collected by centrifugation at 500 x g for 5 min. Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies) following the manufacturer's instructions. Complementary DNA (cDNA) was generated with random primers and the target cDNA sequences were amplified by quantitative PCR in a Mx3000P Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Briefly, total RNA (1 µg) was used for each RT reaction. The 20 µl PCR reaction mixture contained 10 µl of SYBR Premix, 1 µl of each primer and 2 µl of cDNA. Sequences of primers were as follows: forward, 5'-ACCTGAATACAAAATCGAGCCA-3' and reverse 5'-TTGGATGCCGATGTACCTCCT-3' (thymidylate synthase); TS); Forward, 5'-GGCTATCTCTCGAG GTGACATTTTA-3' and reverse, 5'-GCTTTATCATGTT TATGGTGAGGTG-3' (excision repair cross-complementing 1; ERCC1); Forward, 5'-TCCCGAACCAGTATCGGGA-3' and reverse, 5'-CCTCCTTTTCTGTCGCTTCG-3' (topoisomerase 1; TOP1); Forward, 5'-GGCTATCTCTCACAGT GACTTTTA-3' and reverse, 5'-GCTTTATCATGTTATGTT GCATGGT-3' (breast cancer susceptibility gene 1; BRCA1); Forward, 5'-CGAGTAAAGCATGAAACCGA-3' and reverse, 5'-CTACTCAATACGCTTCCTCCCA-3' (uracil phosphoribosyltransferase; OPRT); Forward, 5'-CCATGGAAAGGCG TGGGG-3' and reverse, 5'-CAAAGTTGTCATGGATGA CC-3' (glyceraldehyde 3-phosphate dehydrogenase; GAPDH). The PCR conditions were 95°C for 30 sec followed by 45 cycles at 95°C for 5 sec and 60°C for 20 sec and, finally, followed by the dissociation curve program (95°C for 10 sec at 55-95°C with a heating rate of 0.1°C/Sec and continuous fluorescence measurement). Relative gene expression quantifications were calculated according to the comparative Ct method using GAPDH as an endogenous control and cells without cinnamaldehyde treatment as calibrators. Final results were determined by the formula 2^{-ΔΔCt} (32) and were analyzed with the Stratagene (LaJolla, CA, USA) analysis software.

Statistical methods. Statistical comparisons were performed using the Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Cytotoxicity of cinnamaldehyde and chemotherapeutic treatment on LoVo and HT-29 cells. The cytotoxicity of each drug was examined individually in LoVo and HT-29 cell lines. As expected, cinnamaldehyde and each chemotherapeutic agent individually increased the cytotoxicity in the two cell lines in a dose-dependent fashion. Table I displays the IC_{50} doses for LoVo and HT-29 cell lines following exposure to either cinnamaldehyde or each chemotherapeutic agent. The response of LoVo cells to these drugs (except IRI, which is discussed separately below) tended to be weaker than that of HT-29 cells, suggesting that the genetic makeup of cells is important in the response to drug treatment. Next, the obtained IC_{50} concentrations were used to generate fixed ratios for subsequent combination agent studies and for the calculation of CIs.

Effect of combined cinnamaldehyde and chemotherapeutic treatment on LoVo and HT-29 cells. To explore whether cinnamaldehyde is able to enhance the effects of the chemotherapeutic agents currently used to treat CRC, the effects of 48 h treatment with cinnamaldehyde, 5-FU and OXA individually and in combination were examined. The combination ratios were designed to approximate the IC_{50} ratios of the individual agents, so that the contribution of each compound in the combination to the antiproliferative effect was roughly the same (33). Fig. 1 shows the dose-response curves for LoVo (Fig. 1A and B) and HT-29 (Fig. 1C and D) cell lines exposed to cinnamaldehyde and chemotherapeutic agents individually and in combination. For the two cell lines, decreases in cell survival was more pronounced when cells were treated with cinnamaldehyde and chemotherapeutic agents than when only a chemotherapeutic agent was applied. To fully evaluate the nature of the interaction between cinnamaldehyde and chemotherapeutic agents, we analyzed the combination of the two drugs using media effect analysis, which resolves the degree of synergy, additivity, or antagonism. These results are displayed in Fig. 2. We failed to detect the effect of cinnamaldehyde and IRI combination treatment on the two cell lines as IRI therapy had a weak antagonistic relationship (the linear correlation coefficient >1) and weak reproducibility in the two cell lines.

Apoptotic effects of cinnamaldehyde and chemotherapeutic agents. To test the hypothesis of whether cinnamaldehyde in combination with chemotherapeutic agents is able to increase cell death by inducing apoptosis, flow cytometric analysis was performed. The double staining with Annexin V-FITC and PI was employed to distinguish the apoptotic cells from others. The percentage of early apoptotic cells produced by the treatment with individual chemotherapeutic agents was markedly increased by the presence of cinnamaldehyde, indicating that the simultaneous treatment with cinnamaldehyde and chemotherapeutics induces apoptosis in a synergistic manner (Fig. 3). For example, the percentage of apoptotic (early and late apoptosis) LoVo cells induced by cinnamaldehyde and 5-FU individually was 7.6 and 44.79%, respectively, whereas the percentage induced by the combination of cinnamaldehyde plus 5-FU was 92.7%.

Effect of cinnamaldehyde on the mRNA expression of drug-metabolizing genes. In an attempt to explain the mechanisms underlying the synergistic interaction between cinnamaldehyde and chemotherapeutic agents, we hypothesized that cinnamaldehyde may affect the expression of chemotherapeutic drug-metabolizing genes (i.e., ERCC1, TS, BRCA1, OPRT and TOP1) in CRC by affecting its sensitivity to these drugs. Following incubation with cinnamaldehyde and each chemotherapeutic agent individually at their respective IC_{50} or in combination for 48 h, mRNA expression of these genes was analyzed in LoVo and HT-29 cells.
Table I. IC\textsubscript{50} doses for cinnamaldehyde and chemotherapeutic agents.

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Cinnamaldehyde</th>
<th>5-FU</th>
<th>OXA</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT-29</td>
<td>9.12±0.46</td>
<td>8.16±0.30</td>
<td>6.63±1.86</td>
</tr>
<tr>
<td>LoVo</td>
<td>9.48±0.10</td>
<td>2.91±0.46</td>
<td>7.05±0.67</td>
</tr>
</tbody>
</table>

OXA, oxaliplatin; 5-FU, 5-fluorouracil.

Figure 1. Dose-response curves of cinnamaldehyde and chemotherapeutic agents individually or in combination in (A and B) LoVo and (C and D) HT-29 cells. Each data point represents at least three independent experiments; bars, SD. (A and C), Cinnamaldehyde plus 5-FU; (B and D), cinnamaldehyde plus OXA. 5-FU, 5-fluorouracil; OXA, oxaliplatin; SD, standard deviation.

Figure 2. CI values at different levels of growth inhibition effect (FA) in (A and B) LoVo and (C and D) HT-29 cells. Each data point represents at least three independent experiments; bars, SD. (A and C), Cinnamaldehyde plus 5-FU; (B and D), cinnamaldehyde plus OXA. FA, fraction affected; 5-FU, 5-fluorouracil; OXA, oxaliplatin; SD, standard deviation; CI, combination index.
genes in HT-29 and LoVo cells was assessed by quantitative RT-PCR.

As displayed in Fig. 4, the expression of ERCC1, TS, BRCA1, and TOPO1 was significantly decreased while the expression of OPRT was significantly increased following the treatment with cinnamaldehyde individually. Furthermore, we also compared the mRNA expression of drug-metabolizing genes in LoVo and HT-29 cells. The results of this analysis showed that TS, BRCA1 and ERCC1 mRNA expression in HT-29 cells was lower while the OPRT mRNA expression was higher in HT-29 cells when compared with the expression of these genes in the LoVo cell line.

**Discussion**

Currently, CRC treatment is based on two major new drugs: IRI and OXA. These two chemotherapeutics in combination with 5-FU demonstrate a clear clinical benefit. Nevertheless, the three chemotherapeutic treatments have limited effectiveness due to dosage restrictions as the result of observed toxicity. Numerous plant-derived compounds have been studied for their potential chemopreventive properties and are pharmaceutically safe. Recent studies have suggested that these compounds, including genistein, curcumin, emodin, etc., may be used to sensitize tumor cells to chemotherapeutic agents by inhibiting pathways that lead to treatment resistance (17).

The data presented in this study demonstrated a synergistic interaction between cinnamaldehyde and a series of chemotherapeutic agents in two CRC cell lines. Indeed, the positive affect of cinnamaldehyde combination treatment with other drugs was observed previously in human hepatoma PLC/PRF/5 cells in vitro (28). In our study, HT-29 cells were more sensitive to treatment with cinnamaldehyde, 5-FU and OXA as well as their combinations. For its part, LoVo cells also demonstrated synergistic effects of treatment with these drug combinations, however only in certain concentration ranges, while at other concentration ranges an antagonistic effect was observed.

Several previous studies have demonstrated that the effect of antitumor drug combinations may vary depending on the...
tumor cell line tested (34,35). In the present study, a synergistic interaction of cinnamaldehyde and chemotherapeutic agents was observed in two different differentiated CRC cell lines.

Furthermore, we have examined the observed antitumor effect of combined cinnamaldehyde and chemotherapeutic agents at the level of gene expression. Since several drug-metabolizing genes have been demonstrated to be prognostic markers for 5-FU, OXA and IRI CRC therapy, we have decided to examine the effect of cinnamaldehyde addition on their mRNA expression (36-39).

High TS expression level was demonstrated to be associated with the resistance to 5-FU therapy and poor clinical outcome (36,37). Although certain studies have shown opposite results using cancer cell lines or CRC tissue (40,41), a meta-analysis (42) demonstrated that TS expression level was considered to be one of the most important markers of 5-FU response.

In vivo and in vitro studies have demonstrated that OPRT is one of the key enzymes in 5-FU metabolism and its active metabolite phosphorylation is necessary to inhibit cellular DNA synthesis and induce RNA dysfunction (43). In addition, OPRT mRNA expression predicts the sensitivity to 5-FU (i.e., patients with high OPRT expression have a higher sensitivity to 5-FU treatment and are more likely to benefit from it) (44,45).

The cytotoxic effects of platinum agents are principally attributable to the formation of intrastrand adducts leading to DNA damage (25). ERCC1 is a critical element of the DNA repair pathway. High ERCC1 expression is associated with resistance to platinum-containing therapy in human ovarian (46), lung (47) and gastric (38) cancers. ERCC1 has been demonstrated to be an independent prognostic marker of platinum-based chemotherapy (48).

The BRCA1 gene is located on human chromosome 17 (17q12-21) and BRCA1 mutations have been associated with the development of breast and ovarian cancers (40). In addition, BRCA1 expression was associated with the efficacy of platinum and anti-microtubule chemotherapy (39). Indeed, high BRCA1 expression was observed in tumor cells sensitive to taxane, while low BRCA1 expression was present in tumor cells sensitive to platinum-based drug treatment (49,50).

IRI is a semi-synthetic soluble camptothecin derivative and acts as a specific inhibitor of TOP1. Specifically, IRI acts in the S-phase (synthesis) of the cell cycle and forms a stable binding complex of TOP1 and DNA causing long DNA strand breaks in cell replication which, in turn, leads to irreversible DNA damage and the death of tumor cells (51).

In the present study, we demonstrated that TS, ERCC1, TOP1 and BRCA1 were downregulated, however OPRT was upregulated in the presence of cinnamaldehyde, suggesting that it may sensitize tumor cells to 5-FU and OXA therapy.

We have examined the apoptotic effects of cinnamaldehyde and chemotherapeutic agents on two CRC cell lines, individually and in combination, to determine whether the observed synergistic antiproliferative effects of the drugs is due to their synergistic effects on apoptosis. Indeed, the results of the apoptosis analysis indicated that cinnamaldehyde appears to be a promising candidate for combination treatment with anticancer drugs, particularly 5-FU and OXA. Nevertheless, the combined treatment with cinnamaldehyde and IRI had antagonistic effects.

These drugs induced DNA damage directly or indirectly (52) and the cell death was predominantly induced via the p53-dependent pathway (53). On the other hand, several studies have demonstrated that cinnamaldehyde induces apoptosis in tumor cells through the activation of the pro-apoptotic B-cell lymphoma 2 family proteins and mitogen-activated protein kinase pathway (54). Another study proposed that cinnamaldehyde induces tumor cell death through the inhibition of NF-κB and AP1 (55). Therefore, the pathway induced by cinnamaldehyde leading to apoptosis may be complementary to that induced by chemotherapeutic agents. This may explain at least in part the synergistic effects of cinnamaldehyde in combination treatment with these drugs. Nevertheless, this hypothesis needs to be further explored by additional studies.

The quantitative determination of synergism or antagonism alone does not provide information regarding how and why synergism or antagonism occurs. Therefore, further studies investigating how cinnamaldehyde affects the expression of drug-metabolizing genes need to be conducted.

In conclusion, to the best of our knowledge, this study is the first to demonstrate that cinnamaldehyde may have a promising role in enhancing the efficacy of either 5-FU or OXA treatment of human CRC. The underlying potential mechanism of action may be through their synergistic effects on apoptosis and the downregulation of chemotherapeutic agent-associated genes. Furthermore, preclinical and clinical studies should provide additional insights and assist in determining the optimal dose and schedule for this combination in clinical use. Nevertheless, it is clear that cinnamaldehyde holds considerable promise as an adjuvant to conventional chemotherapy.

Acknowledgements
This project was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

References


